| Literature DB >> 28922577 |
Madia L Stama1, Enza Lacivita1, Liliya N Kirpotina2, Mauro Niso1, Roberto Perrone1, Igor A Schepetkin2, Mark T Quinn2, Marcello Leopoldo1.
Abstract
Formyl peptide receptor 2 (FPR2) is a G protein coupled receptor belonging to the N-formyl peptide receptor (FPR) family that plays critical roles in peripheral and brain inflammatory responses. FPR2 has been proposed as a target for the development of drugs that could facilitate the resolution of chronic inflammatory reactions by enhancing endogenous anti-inflammation systems. Starting from lead compounds previously identified in our laboratories, we designed a new series of ureidopropanamide derivatives with the goal of converting functional activity from agonism into antagonism and to develop new FPR2 antagonists. Although none of the compounds behaved as antagonists, some of the compounds were able to induce receptor desensitization and, thus, functionally behaved as antagonists. Evaluation of these compounds in an in vitro model of neuroinflammation showed that they decreased the production of reactive oxygen species in mouse microglial N9 cells after stimulation with lipopolysaccharide. These FPR2 ligands may protect cells from damage due to inflammation-associated oxidative stress.Entities:
Keywords: antagonists; inflammation; oxidative stress; receptors; ureidopropanamide
Mesh:
Substances:
Year: 2017 PMID: 28922577 PMCID: PMC5909973 DOI: 10.1002/cmdc.201700429
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.466